National PROspective Infrastructure for Renal Cell Carcinoma (PRO-RCC) (PRO-RCC)
PROspective Renal Cancer Cohort (PRO-RCC)
Sponsor: Bristol-Myers Squibb
This observational or N/A phase trial investigates Renal Cancer and Renal Cell Cancer Metastatic and is currently actively recruiting participants. Bristol-Myers Squibb leads this study, which shows 8 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Recruiting
-
Jul 2025 — Sep 2025 [monthly]
Recruiting
-
Sep 2024 — Jul 2025 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Feb 2024 — Jul 2024 [monthly]
Recruiting
▶ Show 3 earlier versions
-
Feb 2023 — Feb 2024 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Jun 2022 — Feb 2023 [monthly]
Not Yet Recruiting
-
May 2022 — Jun 2022 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
- Comprehensive Cancer Centre The Netherlands
- Ipsen
- Merck Sharp & Dohme LLC
- PROspective Renal Cancer Cohort Foundation
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .